{"id":"W4397049554","doi":"10.1016/j.jaip.2024.05.016","title":"Exploring Definitions and Predictors of Response to Biologics for Severe Asthma","year":2024,"lang":"en","type":"article","venue":"The Journal of Allergy and Clinical Immunology In Practice","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"ca_institutions":"Vancouver General Hospital; Vancouver Hospital and Health Sciences Centre; University of British Columbia","funders":"UCB Pharma; Efficacy and Mechanism Evaluation Programme; Sanofi Genzyme; Genentech; Seqirus; Shionogi; Canadian Institutes of Health Research; Kuwait Foundation for the Advancement of Sciences; Michael Smith Health Research BC; Celltrion; Pfizer; Incyte; Optimum Patient Care; AstraZeneca; Allergy Therapeutics; Novartis Pharmaceuticals UK Limited; AKL Research and Development; CSL Behring; British Columbia Lung Association; Canadian Thoracic Society; Regeneron Pharmaceuticals; Grifols; Cerecor; Singapore General Hospital; European Respiratory Society; American Thoracic Society; Chiesi Farmaceutici; Covis Pharma; Novartis Pharma; Glenmark Pharmaceuticals; Danone; Gilead Sciences; Celltrion Healthcare; Eli Lilly and Company; Sanofi; Orient Europharma; GlaxoSmithKline; Amgen; Medical Research Council; Teva Pharmaceutical Industries","keywords":"Medicine; Asthma; Exacerbation; Cohort; Intensive care medicine; Internal medicine","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01436726,0.000601872,0.0006847493,0.002666305,0.0006897138,0.002155506,0.001243561,0.0008929928,0.001451382],"category_scores_gemma":[0.04510416,0.0002890545,0.001623827,0.001980301,0.001090758,0.002268059,0.002075579,0.002697599,0.00019283],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001025419,"about_ca_system_score_gemma":0.00184619,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002135914,"about_ca_topic_score_gemma":0.002839565,"domain_scores_codex":[0.9890593,0.00670366,0.001549059,0.0005815724,0.001393246,0.0007131515],"domain_scores_gemma":[0.9404386,0.03842071,0.01526433,0.00174042,0.002514634,0.001621329],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003933673,0.00006342889,0.9922976,0.00005183055,0.000183651,0.0000247621,0.0001994755,0.0002805754,0.00006895957,0.0002849993,0.0001842656,0.005967088],"study_design_scores_gemma":[0.0000632531,0.0007393162,0.987,0.0002185165,0.0003772692,0.0003799572,0.0023158,0.005243997,0.0004666428,0.001727249,0.001438904,0.0000291741],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9905509,0.003568999,0.001559312,0.001234471,0.00006034212,0.00004342982,0.000464448,0.00001589833,0.002502301],"genre_scores_gemma":[0.9983252,0.0002535905,0.0008912347,0.00009704626,0.00003905885,0.00002246333,0.0002802332,0.000006273852,0.00008502282],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01436726,"threshold_uncertainty_score":0.07598221,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1270904524881311,"score_gpt":0.3835399576024917,"score_spread":0.2564495051143607,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}